<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025943</url>
  </required_header>
  <id_info>
    <org_study_id>O3DI</org_study_id>
    <nct_id>NCT05025943</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acid Dietary Intervention (O3DI)</brief_title>
  <official_title>Omega-3 Fatty Acid Dietary Intervention for Dyslipidemia of Obesity in Children 10 to &lt;18 Years of Age: O3DI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elevated cholesterol, including triglyceride levels, can lead to the development of&#xD;
      cardiovascular disease in adulthood. A diet that is rich in omega-3 fatty acids (O3FA) can&#xD;
      improve triglyceride levels in a way that is safe and does not require medication.&#xD;
&#xD;
      This is a single-center, prospective, unblinded, randomized-controlled dietary intervention&#xD;
      study to assess the impact of an omega-3 fatty acid diet compared to a standard lifestyle&#xD;
      intervention on serum triglyceride in patients with hypertriglyceridemia. The study consists&#xD;
      of an 8-week dietary treatment period followed by an 8-week observation period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in serum triglyceride level after an 8-week diet intervention compared to baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>The study will test whether omega-3 fatty acid enriched diet is associated with a 20% or greater reduction in serum triglyceride levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change red blood cell omega-3 fatty acid content / index after an 8-week diet intervention compared to baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>Total levels of omega-3 fatty acids in red blood cell membrane phospholipids are measured. Percentages are reported as an index. The study will identify the index/total omega-3 fatty acid in red blood cells following initiation of an omega-3 fatty acid enriched diet.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Standard lifestyle intervention + omega-3 fatty acid enriched diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>American Heart Association Target Diet/Standard Lifestyle Intervention (SLI) + omega-3 fatty acid enriched foods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>American Heart Association Target Diet/Standard Lifestyle Intervention (SLI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet intervention</intervention_name>
    <description>The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.</description>
    <arm_group_label>Standard lifestyle intervention + omega-3 fatty acid enriched diet</arm_group_label>
    <other_name>Standard lifestyle intervention + omega-3 fatty acid enriched diet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.</description>
    <arm_group_label>Standard lifestyle intervention</arm_group_label>
    <other_name>Standard lifestyle intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients who are 10 -17 years of age&#xD;
&#xD;
          2. BMI greater than or equal to the 85th percentile&#xD;
&#xD;
          3. Clinical serum triglyceride level &gt;150 mg/dl and &lt; 500 mg/dl performed between 3&#xD;
             months and 1 week prior to study visit 1&#xD;
&#xD;
          4. Ability to follow the study procedures and adhere to the diet counseling&#xD;
             recommendations&#xD;
&#xD;
          5. Written parental permission and assent are obtained prior to any research procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 2 DM (hemoglobin A1C &gt;6.6%)&#xD;
&#xD;
          2. Isotretinoin use&#xD;
&#xD;
          3. Chronic kidney disease (CKD)&#xD;
&#xD;
          4. Uncontrolled hypothyroidism&#xD;
&#xD;
          5. Warfarin use&#xD;
&#xD;
          6. Liver disease (NAFLD is allowed)&#xD;
&#xD;
          7. Renal disease&#xD;
&#xD;
          8. Corticosteroid use&#xD;
&#xD;
          9. Omega-3 fatty acid use (prescription or supplement)&#xD;
&#xD;
         10. Allergy to fish and/or nuts&#xD;
&#xD;
         11. Currently pregnant or planning to become pregnant during the course of this trial -&#xD;
             confirmed by date of LMP/querying family&#xD;
&#xD;
         12. Any significant medical condition which the investigator believes would interfere with&#xD;
             participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carissa Baker-Smith, MD, MPH, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Cardiac Center, Nemours Children's Hospital Delaware</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours Cardiac Center, Nemours Children's Hospital Delaware</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ed Williams, MS</last_name>
      <phone>302-287-6893</phone>
      <email>edward.williams@nemours.org</email>
    </contact>
    <contact_backup>
      <last_name>Carol Prospero, BS</last_name>
      <phone>302-651-6686</phone>
      <email>cprosper@nemours.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carissa Baker-Smith, MD, MPH, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

